With many biologic drugs treating diseases of old age like cancer and arthritis, whose incidence is on the rise in Europe and the USA, the use of biologics is set to increase - to the extent that this sector is projected to be responsible for driving growth of the pharmaceutical market as a whole through 2012. The complex development and manufacturing processes and/or market dominance commonly associated with biologics means that they are priced at a considerable premium to small-molecule drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze